Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 1.00 |
| ▸ | GBA1 | P04062 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PKLR | P30613 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29428909 | 1.00 | CFTR (1.00) | CFTRGBA1KDM4EGAAMAPT | |
| SCHEMBL3824415 | 0.99 | CFTR (0.98) | CFTRGBA1KDM4EGAAMAPT | |
| SCHEMBL3839480 | 0.97 | CFTR (0.95) | CFTRGBA1KDM4EGAAMAPT | |
| SCHEMBL3825231 | 0.93 | CFTR (0.87) | CFTRGBA1KDM4EGAAMAPT | |
| SCHEMBL3822320 | 0.92 | CFTR (0.86) | CFTRGBA1KDM4EGAAMAPT | |
| SCHEMBL15457326 | 0.92 | CFTR (0.86) | CFTRGBA1KDM4EGAAMAPT | |
| SCHEMBL15790076 | 0.90 | CFTR (0.82) | CFTRGBA1KDM4EGAAMAPT | |
| SCHEMBL3822475 | 0.89 | CFTR (0.81) | CFTRGBA1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL3824562 | 0.89 | CFTR (0.81) | CFTRGBA1KDM4EGAAMAPT | |
| SCHEMBL3821097 | 0.89 | CFTR (0.80) | CFTRGBA1KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925317-B1 | A CFTR CORRECTOR FOR THE TEATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIV DEGLI STUDI PADOVA (IT) | 2019-09-04 | — | — | EP | claimed |
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-08-09 | — | — | US | claimed |
| US-9987256-B2 | CFTR corrector for the treatment of genetic disorders affecting striated muscle | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-06-05 | — | — | US | claimed |
| US-20180055873-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-03-01 | — | — | US | claimed |
| US-20160108406-A1 | METHOD OF REGULATING CFTR EXPRESSION AND PROCESSING | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-04-21 | — | — | US | claimed |
| US-20150328217-A1 | A CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2015-11-19 | — | — | US | claimed |
| US-11988661-B2 | Rapid quantitative test to diagnose polycystic kidney disease | UMC UTRECHT HOLDING, B.V. (NL) | 2024-05-21 | — | — | US | disclosed |
| EP-4245302-A1 | CFTR MODULATORS FOR THE TREATMENT OF VASCULAR DISEASE | Charité - Universitätsmedizin Berlin (DE) | 2023-09-20 | — | — | EP | disclosed |
| US-20210333266-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING, B.V. (NL) | 2021-10-28 | — | — | US | disclosed |
| US-20210333266-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING, B.V. (NL) | 2021-10-28 | — | — | US | disclosed |
| US-11035852-B2 | Identifying drug candidates for treating polycystic kidney disease using organoids generated from primary cells | UMC UTRECHT HOLDING, B.V. (NL) | 2021-06-15 | — | — | US | disclosed |
| US-11035852-B2 | Identifying drug candidates for treating polycystic kidney disease using organoids generated from primary cells | UMC UTRECHT HOLDING, B.V. (NL) | 2021-06-15 | — | — | US | disclosed |
| EP-2925317-B1 | A CFTR CORRECTOR FOR THE TEATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIV DEGLI STUDI PADOVA (IT) | 2019-09-04 | — | — | EP | disclosed |
| US-8642609-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642609-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-04 | — | — | US | disclosed |
| EP-1646615-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1646615-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1646615-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050059687-A1 | Modulators of ATP-Binding Cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2005-03-17 | — | — | US | disclosed |
| WO-2004111014-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | CFTR, CLCN2, ATP4A | CFTR 1/4885GBA1 23/4885KDM4E 4734/4885 |
| US-20150328217-A1 | A CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | CFTR, CLCN2, ATP4A | CFTR 1/4885GBA1 14/4885KDM4E 4745/4885 |
| US-20160108406-A1 | METHOD OF REGULATING CFTR EXPRESSION AND PROCESSING | CFTR, NEDD8, SCNN1B | CFTR 1/4885GBA1 1993/4885KDM4E 3073/4885 |
| US-20050059687-A1 | Modulators of ATP-Binding Cassette transporters | CFTR, ABCB1, ABCC2 | CFTR 1/4885GBA1 575/4885KDM4E 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.